Emerging treatments for autoimmune and neurodegenerative diseases demonstrate encouraging progress. A humanized monovalent antibody therapy targeting anti-NMDA receptor encephalitis has been developed to minimize receptor internalization and improve safety profiles. Additionally, Skye Bioscience is progressing preclinical data for a CB1 antibody aimed at metabolic disorders including obesity and diabetes. Research into systemic sclerosis has revealed immune cell heterogeneity that informs potential personalized interventions. Furthermore, novel epigenetic insights into pulmonary hypertension of the newborn point to new therapeutic targets for this critical neonatal condition.